[The treatment of ENT phlogosis: seaprose S vs. nimesulide].
In the present multicentre study, the antiphlogistic activity of seaprose S was assessed according to an experimental design of the controlled type versus nimesulide in patients with phlogistic pathology of ENT relevance and in patients undergoing otoiatric surgical operations. One hundred and sixty patients (87 M, 73 F) were treated with seaprose S in 30 mg tablets (3tab/day) while 160 patients (95 M, 65 F) were treated with nimesulide in 100 mg (2 tab/day). The treatment lasted 7 days. At the beginning of the study, on the 3rd, 7th and 14th day (follow-up) the most significant signs and symptoms present in the pathological forms under consideration were evaluated. Common haematological and haematochemical laboratory parameters were also evaluated and any side effects occurring during the treatment were recorded. Considering the efficacy demonstrated, it was shown how the two drugs used possess an analogous action (NS) and are always able to exert positive control over the symptoms under examination. Administering seaprose S there were 9 cases of unexpected events (5.6%) while with nimesulide 26 patients (16.3%) showed problems of intolerance, with a highly significant statistical difference (p < 0.01) between the two groups. The analysis of the data obtained allows us thus to support the therapeutic use of seaprose S in the treatment of phlogosis of ENT relevance, since it has shown efficacy comparable to that of a NSAID such as nimesulide, but with greater safety.
Antonelli
A
A
Clinica ORL, Brescia.
Cimino
A
A
Cimino
A
A
Di Girolamo
A
A
Filippi
P
P
Filippin
S
S
Galetti
G
G
Marchiori
C
C
Marcucci
L
L
Mira
E
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001799:Blood Sedimentation / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002558:Cerebrospinal Fluid Otorrhea / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D002559:Cerebrospinal Fluid Rhinorrhea / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D007758:Ear, Inner / Q000187:drug effects / Q000503:physiopathology; D004432:Ear, Middle / Q000503:physiopathology / Q000601:surgery; D004433:Earache / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007830:Larynx / Q000503:physiopathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010033:Otitis Media / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D010256:Paranasal Sinuses / Q000503:physiopathology*; D010614:Pharynx / Q000503:physiopathology* / Q000601:surgery; D012107:Research Design; D012140:Respiratory Tract Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D012697:Serine Endopeptidases / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013449:Sulfonamides; C022624:Seaprose S; D012697:Serine Endopeptidases; C012655:nimesulide
Il trattamento delle flogosi in ORL-seaprose s vs nimesulide.